Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vigil Neuroscience Inc ( (VIGL) ) has shared an announcement.
On May 21, 2025, Vigil Neuroscience, Inc. entered into a merger agreement with Sanofi, where Vigil will become a wholly-owned subsidiary of Sanofi. The merger’s completion is contingent upon several conditions, including stockholder approval at a virtual meeting on August 4, 2025, following the expiration of the HSR Waiting Period on July 16, 2025.
The most recent analyst rating on (VIGL) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Vigil Neuroscience Inc stock, see the VIGL Stock Forecast page.
Spark’s Take on VIGL Stock
According to Spark, TipRanks’ AI Analyst, VIGL is a Underperform.
Vigil Neuroscience Inc’s stock score is primarily affected by its weak financial performance, characterized by no revenue generation and negative cash flows. The technical analysis shows some short-term positive momentum, but valuation concerns and the overbought condition suggest caution. The lack of earnings call and corporate events data means these factors did not influence the score.
To see Spark’s full report on VIGL stock, click here.
More about Vigil Neuroscience Inc
Vigil Neuroscience, Inc. is a Delaware-based company operating in the biotechnology industry, focusing on developing treatments for neurodegenerative diseases.
Average Trading Volume: 1,427,091
Technical Sentiment Signal: Buy
Current Market Cap: $384.4M
For a thorough assessment of VIGL stock, go to TipRanks’ Stock Analysis page.